Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Twist Bioscience Corp — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.5 (market cap $41.24B), while Twist Bioscience Corp trades at $158 (market cap $10.32B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 4× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Twist Bioscience Corp for 27 Days on average.
| IEF | TWST | |
|---|---|---|
Market Cap | $41.24B | $10.32B |
Volume | 9,141,967 | 5,894,998 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $205.00 |
52-Week Low | $88.92 | $25.45 |
Typical Hold Time | 108 Days | 27 Days |
Enterprise Value | — | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.11, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bearish trend with moving averages overwhelmingly negative, though oscillators suggest potential oversold conditions. Recent dividend distributions of $0.31-$0.33 per share provide income support. The bond ETF faces headwinds from rising Treasury yields and inflation concerns, with market sentiment leaning defensive amid ongoing bond market volatility.
The outlook remains cautious as IEF navigates the highest Treasury yields in decades. While current yields create potential entry points for income-focused investors, persistent inflation and Federal Reserve policy uncertainty pose significant risks. The ETF's defensive positioning may appeal during market turbulence, but further yield increases could pressure prices lower.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
